
11:26 EDT Xilio Therapeutics (XLO) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics | 7.56 | -3.05 | -28.76% |
| Name | Price | % Change | |
|---|---|---|---|
| $7.56 | -28.76% |

11:26 EDT Xilio Therapeutics (XLO) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks

11:21 EDT Xilio Therapeutics (XLO) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top

Xilio Therapeutics (XLO) announced that the first patient has been dosed in its Phase 1/2 clinical trial evaluating XTX501, a PD-1/masked IL-2 bispecific antibody fusion protein, in patients with metastatic

Raymond James initiated coverage of Xilio Therapeutics (XLO) with an Outperform rating and $16 price target. The firm’s investment thesis rests on its masking technology’s manageable safety profile, a strategic

Xilio Therapeutics (XLO) announced the appointment of Dr. Yariv Houvras as chief medical officer. to joining Xilio, he served as senior vice president of clinical and translational development of Tubulis

Xilio Therapeutics Inc (XLO) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street analysts expect Xilio Therapeutics Inc to post earnings of -$0.59 per share.

Xilio Therapeutics (XLO) announced the appointment of Ben Harshbarger as chief legal officer. recently, he served as chief legal officer at Astria Therapeutics, Inc. until its acquisition. Published first on

Xilio Therapeutics ( ($XLO) ) just unveiled an announcement. At its annual meeting on June 10, 2026, Xilio Therapeutics rebalanced its classified board by accepting the contingent resignation of Daniel

07:50 EDT Xilio Therapeutics (XLO) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks

Xilio Therapeutics (XLO) announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2, at the American Association for Cancer Research Annual Meeting, taking place from April
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 3, 2027TBA | $53.05M | $-0.81 | $3.67M | 0.03 | -30.04 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.